Steven Cohen Annexon, Inc. Transaction History

Point72 Asset Management, L.P.

$36.6 Billion
Q3 2024

A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Annexon, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 5,326,998 shares of ANNX stock, worth $28.1 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares

5,326,998

Previous 5,989,017 11.05%

Holding current value

$28.1 Million

Previous $29.3 Million 7.46%

% of portfolio

0.09%

Previous 0.08%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$4.49 - $7.2 $2.97 Million - $4.77 Million	-662,019 Reduced 11.05%	5,326,998 $31.5 Million
Q2 2024 Aug 14, 2024	BUY	$4.33 - $6.79 $3.61 Million - $5.65 Million	832,617 Added 16.15%	5,989,017 $29.3 Million
Q1 2024 May 15, 2024	BUY	$4.03 - $7.81 $20.8 Million - $40.3 Million	5,156,400 New	5,156,400 $37 Million
Q1 2023 May 15, 2023	SELL	$3.74 - $7.46 $1.08 Million - $2.15 Million	-288,716 Reduced 38.5%	461,284 $1.78 Million
Q4 2022 Feb 14, 2023	BUY	$4.56 - $6.61 $3.42 Million - $4.96 Million	750,000 New	750,000 $3.88 Million
Q1 2022 May 16, 2022	SELL	$2.73 - $11.94 $2.39 Million - $10.4 Million	-874,752 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$11.49 - $22.0 $1.7 Million - $3.25 Million	-147,731 Reduced 14.45%	874,752 $10.1 Million
Q3 2021 Nov 15, 2021	BUY	$16.35 - $23.4 $11 Million - $15.7 Million	671,371 Added 191.21%	1,022,483 $19 Million
Q2 2021 Aug 16, 2021	BUY	$17.81 - $27.48 $1.83 Million - $2.82 Million	102,618 Added 41.3%	351,112 $7.9 Million
Q1 2021 May 17, 2021	BUY	$22.0 - $35.01 $5.47 Million - $8.7 Million	248,494 New	248,494 $6.92 Million

Others Institutions Holding ANNX

# of Institutions

146

Shares Held

102M

Call Options Held

178K

Put Options Held

159K

View Full List

About Annexon, Inc.

Ticker ANNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,617,700
Market Cap $251M
Description
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated n...

More about ANNX

Track Steven Cohen's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Account